Discussions by the Ministry of Health, Labor and Welfare’s (MHLW) study group on the generic industry structure are reaching the last lap. Its final report - a draft of which will be presented later this month - is expected to…
HOME > LATEST
LATEST
-
ARCHIVE MEDICAL FACILITIES & NURSING CARE NEWS IN BRIEF
March 18, 2002
-
ARCHIVE REGULATORY NEWS IN BRIEF
March 18, 2002
-
ARCHIVE New NHI Prices to Be Effective on April 1
March 18, 2002
-
ARCHIVE Committee to Propose Intellectual Property Strategy by Summer
March 18, 2002
-
COMMENTARY BARKER ON DRUGS (3)
March 11, 2002
-
ARCHIVE NHI Price Revision in April Will Hit Drug Companies Hard: Mr Fujiyama of FPMAJ
March 11, 2002
-
ARCHIVE Kuraya Sanseido Aims at Consolidated Sales of \1,330 Bil. in FY2004
March 11, 2002
-
ARCHIVE Hokuriku: Sales Increase by 22% to \24.9 Bil.
March 11, 2002
-
ARCHIVE GE Maker Lost the Game: Mr Sawai
March 11, 2002
-
ARCHIVE Otsuka's POCARI Drink Inhibits Increases in Blood Viscosity
March 11, 2002
-
ARCHIVE New SMO Industry Organization to Be Created in April
March 11, 2002
-
ARCHIVE Sunstar to Report Anti-allergic Effects of Persimmon Leaf Extract
March 11, 2002
-
ARCHIVE SSRI 20th Anniversary Seminar
March 11, 2002
-
ARCHIVE Glaucoma Testing Not Conducted in 80% of Municipalities in Tokyo
March 11, 2002
-
ARCHIVE RAD-AR Proposes to Korosho to Use Reexamination Data to Construct Database
March 11, 2002
-
ARCHIVE MEDICAL FACILITIES & NURSING CARE NEWS IN BRIEF
March 11, 2002
-
ARCHIVE BUSINESS NEWS IN BRIEF
March 11, 2002
-
ARCHIVE MEDICAL DEVICE NEWS IN BRIEF
March 11, 2002
-
ARCHIVE 7 Drugs Approved, Including Sivelestat
March 11, 2002
-
ARCHIVE WORLD NEWS IN BRIEF
March 11, 2002
ページ
Whenever an excellent employee or leader leaves, it’s a blow to your organization.The departure of staff is an inevitable part of business, but in a fiercely competitive recruitment landscape like Japan, employee retention is a priority.Not only does retaining staff…
The Japanese health ministry on December 22 approved a batch of medicines for additional indications, including Otsuka Pharmaceutical’s atypical antipsychotic Rexulti (brexpiprazole) and Zenyaku Kogyo’s anti-CD20 antibody Rituxan (rituximab).Rexulti is now newly indicated for the treatment of depression and depressive…
Authorized generic (AG) strategies taken by innovative drug makers might help soften the impact of generic competition in their businesses but such tactics might also accelerate the application of “G1”/“G2” price cuts for their off-patent brand-name medicines, a Jiho tally…
Japan’s health ministry announced new NHI prices to be applied in April under the FY2022 drug price revision in the official gazette on March 4, with the earlier application of so-called “G1” price cuts to be implemented for the first…